Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials

Faraidoon Haghdoost, Francesca Puledda, David Garcia-Azorin, Eva-Maria Huessler, Roberta Messina & Patricia Pozo-Rosich
BackgroundSeveral novel treatments targeting the calcitonin gene-related peptide pathway have been developed for migraine. We evaluated the efficacy of these medications, including atogepant, rimegepant, erenumab, eptinezumab, fremanezumab, and galcanezumab, for the prevention of migraine via network meta-analysis.MethodsDatabases, including MEDLINE via PubMed, EMBASE, and Cochrane central, were systematically reviewed, and all eligible phase 3 randomised controlled trials were included.ResultsNineteen studies (n = 14,584 participants) were included. Studies included episodic (n = 11) and chronic (n =...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.